Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet

Prashant Tembhare1, Yajamanam Badrinath1, Sitaram Ghogale1, Papagudi Ganesan Subramanian1

1 Hematopathology Laboratory, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai
Publication Name:  Current Protocols in Cytometry
Unit Number:  Unit 6.38
DOI:  10.1002/cpcy.15
Online Posting Date:  April, 2017
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The clinical use of flow cytometric DNA ploidy assay has been extended towards stratifying the risk of diseases, such as monoclonal gammopathies or B cell acute lymphoblastic leukemia, and to detect circulating tumor cells, both of which require detection of minute cell populations. This unit describes a protocol for determining DNA ploidy in fixed samples with simultaneous surface immunophenotyping. It is an easy method for simultaneous 6‐ to 8‐color immunophenotyping and DNA content analysis using FxCycle Violet (FCV; DAPI) dye. This protocol is a one‐step modification of routine multicolor immunophenotyping that includes surface staining followed by fixation and then DNA staining with FCV. It utilizes mature lymphocytes from the sample as an internal control for determination of DNA index. It is a sensitive method that allows DNA‐ploidy determination and cell cycle analysis in a rare tumor population as low as 100 events, as well as DNA ploidy determination in various subsets of hematopoietic cells in the same sample based on their immunophenotype. © 2017 by John Wiley & Sons, Inc.

Keywords: DNA ploidy; FxCycle Violet; DAPI; flow cytometry; 6‐ to 8‐color immunophenotyping

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Significance Statement
  • Basic Protocol 1:  
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1:  

  Materials
  • Sample to be processed: Any unfixed sample like peripheral blood (PB), bone marrow aspirate (BM), fine needle aspirate (FNA), body fluids within 24 to 48 hr of collection can be processed for the DNA‐ploidy using this method (this protocol has been standardized using EDTA anticoagulated bone marrow aspirate and peripheral blood samples)
  • Red cell lysing reagent (see recipe)
  • Phosphate buffer saline (PBS) solution with 0.5% albumin (PBS‐A; see recipe)
  • Antibodies: Antibodies conjugated with fluorochromes that can be excited with blue and red laser depending upon the instrument; antibodies conjugated with fluorochromes excited with violet laser should be avoided due to significant spectral overlap with FCV (see Table 6.38.1 for details on the antibodies used)
  • Medium‐A of Fix and Perm kit (Invitrogen, cat. no. GAS002S100)
  • Reconstituted FCV (see recipe)
  • Instrument quality control beads and set up beads: CS&T Beads (Becton Dickinson, cat. no. 642412), flowcheck beads (BC instrument, cat. no. A63493), and SPHERO Rainbow Calibration Particles (Spherotech, cat. no. RCP‐30‐5A)
  • 12 × 75–mm polystyrene tubes
  • 15‐ml polypropylene tubes (Tarsons, cat. no. 546021)
  • Centrifuge
  • Pipets
  • Vortex
  • Neubauer chamber
  • Flow cytometer equipped with a 405‐nm violet laser, 488‐nm argon‐ion lasers, and a 635‐nm red laser, as a fluorescence excitation source like FACS Canto‐II (BD), Navios (BC): this protocol has been used on both the instruments.
  • Flow cytometry analysis software: e.g., Kaluza, version 1.3 (Beckman Coulter)
Table 6.8.1   MaterialsDetails for Antibodies Used for B cell Precursor Acute Lymphoblastic Leukemia (B‐ALL) and Multiple Myeloma (MM) a

Fluorochrome FITC PE ECD/PE‐CF594 PC5.5 PC7 APC APC‐Alexa Fluor 700 APC‐Alexa Fluor 750
B cell precursor acute lymphoblastic leukemia antibody and DNA ploidy panel
Antibody/reagent FxCycleViolet CD58 CD86 CD25 CD34 CD10 CD19 CD45 CD38
Catalog number F_10347 IM1218U 555658 562 403 347 203 A46527 IM2470 A71117 A86049
Clone AICD58 2331(FUN‐1) M‐A251 8G12 ALB1 J3‐119 J.33 LS198‐4‐3
Isotype control IgG2a IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1
Company Invitrogen BC BD BD BD BC BC BC BC
Multiple Myeloma and DNA ploidy panel
Antibody/reagent FxCycle Violet x CD81 CD19 CD27 CD56 CD138 CD45 CD38
Catalog number F_10347 x IM2579 A07770 B21444 A 51078 A87787 A71117 A86049
Clone x x JS64 J3‐119 1A4CD27 N901 (HLD‐A6) B‐A38 J.33 LS198‐4‐3
Isotype control x x M IgG1 M IgG1 M IgG1 M IgG1 M IgG1 M IgG1 M IgG1
Company Invitrogen x BC BC BC BC BC BC BC

 aAbbreviations: BC, Beckman Coulter; BD, BD Biosciences.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Allan, R.W., Ansari‐Lari, M.A., and Jordan, S. 2008. DRAQ5‐based, no‐lyse, no‐wash bone marrow aspirate evaluation by flow cytometry. Am. J. Clin. Pathol. 129:706‐713. doi: 10.1309/D2M6Q7BYHWAM1FYQ.
  Almeida, J., Orfao, A., Ocqueteau, M., Mateo, G., Corral, M., Caballero, M.D., Blade, J., Moro, M.J., Hernandez, J., and San Miguel, J.F. 1999. High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br. J. Haematol. 107:121‐131. doi: 10.1046/j.1365‐2141.1999.01685.x.
  Carbonari, M., Tedesco, T., and Fiorilli, M. 2001. A unified procedure for conservative (morphology) and integral (DNA and immunophenotype) cell staining for flow cytometry. Cytometry 44:120‐125. doi: 10.1002/1097‐0320(20010601)44:2%3c120::AID‐CYTO1090%3e3.0.CO;2‐7.
  Corver, W.E., Koopman, L.A., van der Aa, J., Regensburg, M., Fleuren, G.J., and Cornelisse, C.J. 2000. Four‐color multiparameter DNA flow cytometric method to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry 39:96‐107. doi: 10.1002/(SICI)1097‐0320(20000201)39:2%3c96::AID‐CYTO2%3e3.0.CO;2‐X.
  Danielsen, H.E., Pradhan, M., and Novelli, M. 2016. Revisiting tumour aneuploidy—the place of ploidy assessment in the molecular era. Nat. Rev. Clin. Oncol. 13:291‐304. doi: 10.1038/nrclinonc.2015.208.
  Darzynkiewicz, Z. 2010a. Critical aspects in analysis of cellular DNA content. Curr. Protoc. Cytom.56:7.2.1‐7.2.8. doi: 10.1002/0471142956.cy0702s56.
  Darzynkiewicz, Z. 2010b. Cytometry of the cell cycle: In search for perfect methodology for DNA content analysis in tissue specimens. Cell Cycle 9:3395‐3396. doi: 10.4161/cc.9.17.13015.
  Denys, B., van der Sluijs‐Gelling, A.J., Homburg, C., van der Schoot, C.E., de Haas, V., Philippe, J., Pieters, R., van Dongen, J.J., and van der Velden, V.H. 2013. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 27:635‐641. doi: 10.1038/leu.2012.231.
  Hulspas, R. 2010. Titration of fluorochrome‐conjugated antibodies for labeling cell surface markers on live cells. Curr. Protoc. Cytom. 54:6.29.1‐6.29.9. doi: 10.1002/0471142956.cy0629s54.
  Kapuściński, J. and Skoczylas, B. 1978. Fluorescent complexes of DNA with DAPI 4′,6‐diamidine‐2‐phenyl indole, 2HCl or DCI 4′,6‐dicarboxyamide‐2‐phenyl indole. Nucleic Acids Res. 5:3775‐3799.
  Kenney, B., Zieske, A., Rinder, H., and Smith, B. 2008. DNA ploidy analysis as an adjunct for the detection of relapse in B‐lineage acute lymphoblastic leukemia. Leuk. Lymphoma 49:42‐48. doi: 10.1080/10428190701760052.
  Kubista, M., Akerman, B., and Norden, B. 1987. Characterization of interaction between DNA and 4′,6‐diamidino‐2‐phenylindole by optical spectroscopy. Biochemistry 26:4545‐4553. doi: 10.1021/bi00388a057.
  Linden, E., Skoglund, P., and Rundquist, I. 1997. Accessibility of 7‐aminoactinomycin D to lymphocyte nuclei after paraformaldehyde fixation. Cytometry 27:92‐95. doi: 10.1002/(SICI)1097‐0320(19970101)27:1%3c92::AID‐CYTO12%3e3.0.CO;2‐N.
  Lopez‐Otero, A., Ruiz‐Delgado, G.J., Hernandez‐Arizpe, A., Ruiz‐Arguelles, A., and Ruiz‐Arguelles, G.J. 2010. The flow‐cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: A single institution experience. Hematology 15:378‐381. doi: 10.1179/102453310X12719010991669.
  Mancaniello, D. and Carbonari, M. 2008. Immunophenotyping and DNA content analysis of acetone‐fixed cells. Curr. Protoc. Cytom. 46:9.26.1‐9.26.11. doi: 10.1002/0471142956.cy0926s46.
  Nowak, R., Oelschlagel, U., Hofmann, R., Zengler, H., and Huhn, R. 1994. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk. Res. 18:897‐901. doi: 10.1016/0145‐2126(94)90101‐5.
  O. Basu, F.Z., Uma Devi, P., and Streffer, C. 2009. DNA‐Ploidy—Aprognostic factor of acute lymphoblastic leukemia (ALL) in childhood. Asian J. Exp. Sci. 23:33‐38.
  Perez‐Persona, E., Vidriales, M.B., Mateo, G., Garcia‐Sanz, R., Mateos, M.V., de Coca, A.G., Galende, J., Martin‐Nunez, G., Alonso, J.M., de Las Heras, N., Hernandez, J.M., Martin, A., Lopez‐Berges, C., Orfao, A., and San Miguel, J.F. 2007. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110:2586‐2592. doi: 10.1182/blood‐2007‐05‐088443.
  Smith, P.J., Wiltshire, M., and Errington, R.J. 2004.DRAQ5 labeling of nuclear DNA in live and fixed cells. Curr. Protoc. Cytom. 28:7.25.1‐7.25.11. doi: 10.1002/0471142956.cy0725s28.
  Stacchini, A., Demurtas, A., and Aliberti, S. 2014. Immunophenotyping of paucicellular samples. Curr. Protoc. Cytom. 68:9.46.1‐9.46.14. doi: 10.1002/0471142956.cy0946s68.
  Swerts, K., Van Roy, N., Benoit, Y., Laureys, G., and Philippe, J. 2007. DRAQ5: Improved flow cytometric DNA content analysis and minimal residual disease detection in childhood malignancies. Clin. Chim. Acta 379:154‐157. doi: 10.1016/j.cca.2006.12.008.
  Telford, W.G., King, L.E., and Fraker, P.J. 1992. Comparative evaluation of several DNA binding dyes in the detection of apoptosis‐associated chromatin degradation by flow cytometry. Cytometry 13:137‐143. doi: 10.1002/cyto.990130205.
  Tembhare, P., Badrinath, Y., Ghogale, S., Patkar, N., Dhole, N., Dalavi, P., Kunder, N., Kumar, A., Gujral, S., and Subramanian, P.G. 2016. A novel and easy FxCycle violet based flow cytometric method for simultaneous assessment of DNA ploidy and six‐color immunophenotyping. Cytometry A 89:281‐291. doi: 10.1002/cyto.a.22803.
  Vago, P. 1995. Clinical flow cytometric DNA analysis of human solid tumors. Bull. Cancer 82:122‐128.
  Wang, S., Li, N., Heald, P., Fisk, J.M., Fadare, O., Howe, J.G., McNiff, J.M., and Smith, B.R. 2004. Flow cytometric DNA ploidy analysis of peripheral blood from patients with sezary syndrome: Detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue. Am. J. Clin. Pathol. 122:774‐782. doi: 10.1309/8B849FC6PHAP8FDD.
  Wood, B. 2006. 9‐color and 10‐color flow cytometry in the clinical laboratory. Arch. Pathol. Lab. Med. 130:680‐690. http://www.lifetechnologies.com/order/catalog/product/F10347.doi: 10.1043/1543‐2165.
  Yuan, C.M., Douglas‐Nikitin, V.K., Ahrens, K.P., Luchetta, G.R., Braylan, R.C., and Yang, L. 2004. DRAQ5‐based DNA content analysis of hematolymphoid cell subpopulations discriminated by surface antigens and light scatter properties. Cytometry B Clin. Cytom. 58:47‐52. doi: 10.1002/cyto.b.20000.
  Zelenin, A.V., Poletaev, A.I., Stepanova, N.G., Barsky, V.E., Kolesnikov, V.A., Nikitin, S.M., Zhuze, A.L., and Gnutchev, N.V. 1984. 7‐Amino‐actinomycin D as a specific fluorophore for DNA content analysis by laser flow cytometry. Cytometry 5:348‐354. doi: 10.1002/cyto.990050410.
  Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda‐Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B., and Shaughnessy, J.D. Jr. 2006. The molecular classification of multiple myeloma. Blood 108:2020‐2028. doi: 10.1182/blood-2005-11-013458.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library